patient group direction

Size: px
Start display at page:

Download "patient group direction"

Transcription

1 MORPHINE SULPHATE (Oral) v01 1/8 MORPHINE SULPHATE (Oral) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse) Medicines Management Group Date issued 01/02/2013 Review date 31/01/2015 Clinical Publication Category Mandatory - No deviation from document permissible Clinical Requirements Competencies Continuing education Successful completion of a competency assessment in the use of this medicine for the indications stated. Completion of education in both the legal and professional aspects of PGD administration and the supply of medicines. The clinician is responsible for keeping him/herself aware of any changes to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with continued professional development and to work within the limitations of their own individual scope of practice.

2 MORPHINE SULPHATE (Oral) v01 2/8 Clinical Situation Clinical situation Inclusion criteria Exclusion criteria The treatment of moderate to severe pain Adults and children aged 1 year and over with moderate to severe pain. Children under 1 year old. Patients unable to swallow or protect own airway. Delayed gastric emptying Phaeochromocytoma (tumour on adrenal gland) Heart failure secondary to chronic lung disease Acute respiratory depression (Adults <10 breaths per minute, child < 20 breaths per minute) or inadequate tidal volume. Asthma (during an acute exacerbation) Hypotension (actual not estimated) where systolic <90mmHg (adults), <80mmHg (school children), <70mmHg (pre-school children) Head injury with a significantly reduced level of consciousness (GCS<12). Hypersensitivity to morphine or other opiates Risk of paralytic ileus (associated clinical features are little or no abdominal pain/local tenderness, abdominal distension, failure to pass flatus or faeces, vomiting, significantly reduced or absent bowel sounds) Severe hepatic or renal impairment

3 MORPHINE SULPHATE (Oral) v01 3/8 Cautions Naloxone must be available and the appropriate dose for the age/weight of patient must be known before morphine is administered. Histamine is released following morphine administration, this may contribute to its vasodilator effects and may also cause bronchoconstriction, particularly in asthmatics. Patients with: Adrenocortical insufficiency Decreased respiratory reserve (ie COPD) Prostatic hypertrophy Gallstones Myasthenia gravis Cardiac arrhythmias Acute abdomen Pancreatitis Obstructive or inflammatory bowel disorders History of substance misuse (treat only if there is a genuine clinical need) Elderly and debilitated patients who may require a reduced dose. Acute alcohol intoxication and alcoholism. All opioid drugs potentiate the central nervous system depressant effects of alcohol and they should therefore be used with great caution in patients who have consumed a significant amount of alcohol Use with extreme caution (minimal doses) during pregnancy. NOTE not to be used for pain associated with labour where Entonox is the analgesic of choice. Morphine should be given with great caution to patients with chest injuries particularly those with any respiratory difficulty, although if respiration is inhibited by pain, morphine may actually improve respiratory status. Agitation following head injury may be due to acute brain injury, hypoxia or pain. The decision to administer analgesia to agitated head injured patients is a clinical one. It is essential however; that any such patient who receives analgesia is closely monitored as opiates may cause a disproportionate respiratory depression and hence increase intracranial pressure.

4 MORPHINE SULPHATE (Oral) v01 4/8 Patients taking monoamine oxidase inhibitors (MAOIs) should not be given morphine until their drug information card has been checked. Patients taking antidepressants, anxiolytics, sedatives or major tranquilliser drugs, as these will potentiate the respiratory and cardiovascular depressant effects of morphine. In cardiac pain entonox and IV morphine are the analgesics of choice. Only consider oral morphine when IV access cannot be obtained, and Entonox either cannot be administered or is in. Patients taking other opioid-containing preparations (see NPSA guidance below). Reducing Dosing Errors with Opioid Drugs: Opioid medicines are invaluable in the treatment of acute and chronic pain but there are risks if clinicians who supply or administer opioid drugs have insufficient knowledge of the dosage and the requirements of the individual patient concerned. The nature of urgent and emergency care increases this risk as practitioners do not usually have access to the patient notes and will have to rely on the information that they are given by the patient or their carer(s). Opioid drugs include: buphrenorphine, codeine, diamorphine, dipipanone, fentanyl, hydromorphone, meptazinol, methadone, morphine, oxycodone, papaveretum, pethidine and tramadol. These drugs are found in a wide variety of presentations including patches which release opioid over a prolonged period. The patient response to opioid drugs can vary widely and is partly dependent on previous doses received. Particular care needs to be taken when checking the safety of increased doses. When supplying or administering an opioid drug clinicians should confirm and record in the patient s notes any recent opioid dose, formulation, frequency of administration and any other analgesic medicines prescribed for the patient. This may be done for example

5 MORPHINE SULPHATE (Oral) v01 5/8 by discussion with the patient and /or their representative, contacting the prescriber or through available medical records. The source of this information must be recorded in the patient s notes. NB When assessing opioid use remember that over the counter medicines may also contain opioid drugs such as codeine, including some cough medicines. Codeine can also be prescribed for diarrhoea so ask about drugs by name. Clinicians must ensure that where a dose increase is intended, that the calculated dose is safe for the patient. The practitioner must record the check in the patient s notes. Clinicians must ensure that they are familiar with the following characteristics of an opioid drug before they prescribe it for a patient: Usual starting dose Frequency of administration Standard dosing increments Symptoms of overdose Common side-effects Side effects Nausea and vomiting Respiratory and cardiovascular depression Pupillary constriction Abdominal pain Seizures Malaise, drowsiness Hypothermia Muscle fasciculation Hypotension Muscle rigidity Other side-effects include constipation, anorexia, difficulty in micturation, ureteric or biliary spasm, dry mouth, headache, facial flushing, vertigo, bradycardia, tachycardia, palpitations, postural hypotension, hallucinations, hypothermia, dysphoria, mood changes, dependence, decreased libido or potency, rashes, pruritis.

6 MORPHINE SULPHATE (Oral) v01 6/8 Action if excluded Action if patient declines If patient meets exclusion criteria: Explain reason to patient/carer Consider alternative pain management Refer to an ECP or Doctor Document the specific exclusion and any action taken on the PCR. If patient declines treatment or advice ensure that the PCR details: The advice given by the clinician Details of any referral made The intended actions of the patient (including parent or guardian)

7 MORPHINE SULPHATE (Oral) v01 7/8 Description of Treatment Generic name Presentation Route Morphine sulphate Oral solution 10mg in 5ml (2mg in 1ml) Oral Method Administration Supply Dose Adults and children aged 12 years and over: 10mg to 20mg (NB Total quantity of morphine administered by one paramedic, parenteral and/or oral, to an individual patient must not exceed 20mg) Frail elderly patients may require a reduced dose of 5mg Children 11 years and under: AGE DOSE VOLUME 11 years 7 milligrams 3.5ml 10 years 6 milligrams 3.0ml 9 years 6 milligrams 3.0ml 8 years 5 milligrams 2.5ml 7 years 5 milligrams 2.5ml 6 years 4 milligrams 2.0ml 5 years 4 milligrams 2.0ml 4 years 3 milligrams 1.5ml 3 years 3 milligrams 1.5ml 2 years 2.0 milligrams 1.0ml 1 years 2.0 milligrams 1.0ml

8 MORPHINE SULPHATE (Oral) v01 8/8 Frequency Duration of treatment The onset of action will be longer for oral morphine than parenteral morphine. Side-effects will not become immediately apparent and may occur up to 15 minutes after administration. For children and adults aged 12 years and over administer up to 10mg oral dose initially. This dose may be reduced to 5mg in frail elderly patients and those with reduced body mass. Note the response and if needed give a further dose of 10mg (5mg frail elderly) after 30 minutes. Single episode of care

9 MORPHINE SULPHATE (Oral) v01 9/8 Follow Up Referral arrangements and safety netting Advice to patients Records References All children given oral morphine sulphate must be admitted. There is no requirement to admit adults, where their condition can be managed in the community. However, the clinician must consider the onward plan after the single dose of oral morphine. The patient should be referred to an ECP, their GP or out-of-hours Doctor for consideration of on-going analgesia. Monitor the patient for pain relief and side-effects Adults who are not admitted must be monitored for at least 20 minutes before they are left at home. If a patient is left at home they must have another adult at home with them. The patient and the responsible adult with them must be told to seek further medical advice if they become generally unwell, if there is no improvement within 48hrs or if there is deterioration in their condition. May cause drowsiness. Adults who are left at home should not drive or operate machinery if affected. Avoid alcoholic drink as this may increase drowsiness Warn that morphine may cause nausea Complete patient clinical record (PCR) Morphine sulphate oral solution 10mg in 5ml is a Schedule 5 controlled drug. Staff must carry out a stock check when issuing morphine sulphate oral solution 10mg in 5ml and ensure that the supply, and the remaining stock balance are recorded as necessary. Any discrepancy in the stock level that is discovered must be reported to your line manager and an investigation instigated as detailed in the Trust s Medicines Management Policy. British National Formulary 64 September 2012 (BNF) JRCALC Guidelines National Patient Safety Agency, Rapid Response Report NPSA/2008/RRR05. Reducing dosage errors with opioid medicines. July 2008.

10 MORPHINE SULPHATE (Oral) v01 10/8 Authorisation Chief Executive Officer Ken Wenman Signature Date 01/02/2013 Medical Director Dr Andy Smith Signature Date 01/02/2013 Pharmaceutical Advisor Sue Oakley Signature Date 01/02/2013 This must be signed by the Chief Executive Officer, Medical Director and Pharmaceutical Advisor to be legally valid.

11 MORPHINE SULPHATE (Oral) v01 11/8 Individual Authorisation (Staff Copy) Individual Signature Date / / Authorising officer Signature Date / / I have read and understood the Patient Group Direction and agree to administer this medicine only in accordance with this document. PGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct. This signed page must be retained by the member of staff, together with the full PGD, which must be available in clinical practice.

12 MORPHINE SULPHATE (Oral) v01 12/8 Individual Authorisation (Trust Copy) Individual Signature Date / / Authorising officer Signature Date / / I have read and understood the Patient Group Direction and agree to administer this medicine only in accordance with this document. PGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct. This signed page copy of the PGD must be retained by the station Clinical Support Officer, Clinical Team Leader or Lead Paramedic in a station file which is available for inspection upon request.

patient group direction

patient group direction DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care

More information

patient group direction

patient group direction DIAZEPAM v01 1/9 DIAZEPAM PGD Details Version 1.0 Legal category Staff grades Approved by CD Benz POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

patient group direction

patient group direction CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

patient group direction

patient group direction NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction PRESERVATIVE-FREE LIDOCAINE v1.0 1/9 PRESERVATIVE-FREE LIDOCAINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Registered Paramedic Registered Nurse Medicines Management Group Date

More information

patient group direction

patient group direction ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

patient group direction

patient group direction REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic

More information

patient group direction

patient group direction NITROFURANTOIN v01 1/12 NITROFURANTOIN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Medicines Protocol RECTAL DIAZEPAM

Medicines Protocol RECTAL DIAZEPAM Medicines Protocol RECTAL DIAZEPAM RECTAL DIAZEPAM v2.0 1/6 Protocol Details Version 2.0 Legal category Staff grades POM Registered Paramedic Registered Nurse Specialist Paramedic (Urgent and Emergency

More information

RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act

RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act 22 January 2019 RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act Dear Healthcare Professional, This notification

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol Hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol Hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Hydrochloride Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need

More information

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE

More information

Medicines Optimisation Strategy

Medicines Optimisation Strategy Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:

More information

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Reviewer No.1 check list for application for addition: Morphine Modified Release (MMR) tablets 10mg, 30mg and 60mg

Reviewer No.1 check list for application for addition: Morphine Modified Release (MMR) tablets 10mg, 30mg and 60mg Reviewer No.1 check list for application for addition: Morphine Modified Release (MMR) tablets 10mg, 30mg and 60mg (1) Have all important studies that you are aware of been included? Yes No The application

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute

More information

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone

Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version

More information

PRESCRIBING ALERT

PRESCRIBING ALERT www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02

More information

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing

More information

Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW

Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,

More information

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure. Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients

More information

Palliative Prescribing - Pain

Palliative Prescribing - Pain Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing

More information

Expiry Date: July 2009 Template Version: Page 1 of 7

Expiry Date: July 2009 Template Version: Page 1 of 7 Salbutamol nebules YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT NPGD2007/355 (supersedes 2004/177) Clinical Condition Indication: Inclusion

More information

PATIENT GROUP DIRECTION (PGD)

PATIENT GROUP DIRECTION (PGD) PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:

More information

Clinician Responsible for Training and Review: Emergency Department Consultant

Clinician Responsible for Training and Review: Emergency Department Consultant Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or

More information

Fact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII

Fact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication

More information

Summary of risk management plan for Dzuveo (Sufentanil (as citrate))

Summary of risk management plan for Dzuveo (Sufentanil (as citrate)) Part VI: Summary of the risk management plan Summary of risk management plan for Dzuveo (Sufentanil (as citrate)) This is a summary of the risk management plan (RMP) for Dzuveo. The RMP details important

More information

Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers

Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers Why you should read this leaflet This leaflet will give you the information necessary to manage your

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET DHC CONTINUS 60mg tablets Dihydrocodeine hydrogen tartrate 1 PRODUCT NAME DHC CONTINUS 60mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Dihydrocodeine hydrogen tartrate 60mg Excipient(s) with known

More information

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride Package leaflet: Information for the user Morfin Abcur 10 mg/ml, solution for injection morphine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains

More information

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also

More information

Your Pharmacy Paracetamol Plus, capsule shaped tablets (caplets)

Your Pharmacy Paracetamol Plus, capsule shaped tablets (caplets) New Zealand Data Sheet Product Description Your Pharmacy Plus, capsule shaped tablets (caplets) 500 mg per tablet & Codeine Phosphate 10 mg per tablet Blister packs of white, capsule-shaped tablets Composition

More information

PARACOD Tablets (Paracetamol + Codeine phosphate)

PARACOD Tablets (Paracetamol + Codeine phosphate) Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s

More information

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

PAIN MANAGEMENT Person established taking oral morphine or opioid naive. PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

Factsheet. Buccolam (midazolam) 10mg in 2mL oromucosal solution. Management of seizures in adult patients

Factsheet. Buccolam (midazolam) 10mg in 2mL oromucosal solution. Management of seizures in adult patients North Central London Joint Formulary Committee Factsheet Buccolam (midazolam) 10 mg in 2 ml oromucosal solution Management of seizures in adult patients Start date: May 2017 Review date: May 2020 Document

More information

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Shared Care Guideline

Shared Care Guideline Shared Care Guideline Midodrine for Orthostatic hypotension and neurocardiogenic syncope Executive Summary Update of Guideline following licencing of drug. The responsibility for initiating midodrine will

More information

. AREAS OF RESPONSIBILITY FOR SHARED CARE

. AREAS OF RESPONSIBILITY FOR SHARED CARE SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the

More information

PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY

PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of

More information

4.4 Special warnings and precautions for use

4.4 Special warnings and precautions for use SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative

More information

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects. Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

Expiry Date: September 2009 Template Version: Page 1 of 7

Expiry Date: September 2009 Template Version: Page 1 of 7 GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:

More information

Palliative Care Impact Survey

Palliative Care Impact Survey September 2018 Contents Introduction...3 Headlines...3 Approach...4 Findings...4 Which guideline are used...4 How and where the guidelines are used...6 Alternative sources of information...7 Use of the

More information

Care of the Dying Management in Severe Renal Failure

Care of the Dying Management in Severe Renal Failure Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is

More information

Adult Opioid Prescribing Guidelines for Acute or Persistent Pain

Adult Opioid Prescribing Guidelines for Acute or Persistent Pain Adult Opioid Prescribing Guidelines for Acute or Persistent Pain Author: Sponsor/Executive: Responsible committee: Consultation & Approval: (Committee/Groups which signed off the policy, including date)

More information

GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET 1. PRODUCT NAME Codeine Phosphate Tablets (PSM) 15 mg, 30 mg & 60 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Codeine Phosphate Hemihydrate BP 15 mg

More information

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally

More information

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen

More information

Prescribing and Administration of Analgesia within Maternity

Prescribing and Administration of Analgesia within Maternity Prescribing and Administration of Analgesia within Maternity CONTENTS Introduction and Who The Guideline Applies To... 2 UHL Paracetamol Prescribing Guideline... 2 Oral dosing... 2 Intravenous dosing...

More information

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an

More information

Read all of this leaflet carefully before you start taking this medicine. If you have any further questions, ask your doctor or pharmacist.

Read all of this leaflet carefully before you start taking this medicine. If you have any further questions, ask your doctor or pharmacist. PACKAGE LEAFLET: INFORMATION FOR THE USER Codeine Phosphate 15mg Tablets BP Codeine Phosphate 30mg Tablets BP Codeine Phosphate 60mg Tablets BP (Codeine Phosphate) Read all of this leaflet carefully before

More information

Version Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by:

Version Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by: PATIENT GROUP DIRECTION (PGD) FOR THE INPATIENT ADMINISTRATION OF ORAL LORAZEPAM TO WORKING AGE AND OLDER PEOPLE (includes persons in a Place of Safety suite) Version Number: 5 Patient Group Direction

More information

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient

More information

Patient Group Direction (PGD)

Patient Group Direction (PGD) Patient Group Direction (PGD) Supply of Nitrofurantoin for uncomplicated Urinary Tract Infections in females aged 16 years and over (Telford and Wrekin and Shropshire Pharmacies Only) For the supply of

More information

Care of the Dying Management in Severe Renal Failure

Care of the Dying Management in Severe Renal Failure Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117

More information

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage

More information

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name

More information

Annex C. (variation to nationally authorised medicinal products)

Annex C. (variation to nationally authorised medicinal products) Annex C (variation to nationally authorised medicinal products) Annex I Scientific conclusions and grounds for variation to the terms of the marketing authorisations Scientific conclusions Taking into

More information

Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate)

Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Guidance for naltrexone prescribing

Guidance for naltrexone prescribing Document level: Drug Alcohol (Trustwide) Code: DA7 Issue number: 2 Guidance for naltrexone prescribing Lead executive Authors details Type of document Target audience Document purpose Lead Clinical Director

More information

Each tablet contains 30mg Codeine Phosphate Ph Eur. Excipient with known effect: Also contains mg of lactose.

Each tablet contains 30mg Codeine Phosphate Ph Eur. Excipient with known effect: Also contains mg of lactose. 1 NAME OF THE MEDICINAL PRODUCT Codeine Phosphate Tablets BP 30mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30mg Codeine Phosphate Ph Eur. Excipient with known effect: Also contains

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION Supply / Administration of: By: Pharmacists Azithromycin 250mg capsules for Chlamydia In: Community Pharmacy It is the responsibility of the professional working under this PGD

More information

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Oxycodone is a strong pain killer used for treatment of moderate to severe pain. It is believed that globally 1 in 5 adults suffer

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance

More information

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice. Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Sudden pain is an unpleasant sensation resulting from physical hurt caused by injuries of the body, illness or emotional illness.

More information

Clinician Responsible for Training and Review: Emergency Department Consultant

Clinician Responsible for Training and Review: Emergency Department Consultant Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This

More information

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared

More information